Published in Cancer Res on July 29, 2011
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol (2012) 1.58
Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res (2012) 1.52
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell (2013) 1.15
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med (2015) 1.07
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol (2014) 1.04
Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol (2012) 1.01
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer (2013) 0.95
Notching on Cancer's Door: Notch Signaling in Brain Tumors. Front Oncol (2015) 0.95
Endothelial cell metabolism and implications for cancer therapy. Br J Cancer (2012) 0.93
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res (2012) 0.92
Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. J Biol Chem (2014) 0.92
Eph receptors as therapeutic targets in glioblastoma. Br J Cancer (2014) 0.88
The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol (2014) 0.88
The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation. PLoS One (2011) 0.87
The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma. Oncotarget (2016) 0.87
Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer (2016) 0.86
Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol (2013) 0.86
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci (2014) 0.86
Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers (2013) 0.85
γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. Br J Cancer (2012) 0.85
Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas. Cancer Res (2014) 0.85
Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget (2014) 0.84
ROS, Notch, and Wnt signaling pathways: crosstalk between three major regulators of cardiovascular biology. Biomed Res Int (2014) 0.84
A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis (2015) 0.84
Clinical implications of DLL4 expression in gastric cancer. J Exp Clin Cancer Res (2013) 0.84
Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol (2014) 0.83
Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma. PLoS One (2015) 0.83
Compensatory angiogenesis and tumor refractoriness. Oncogenesis (2015) 0.83
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition. J Hematol Oncol (2013) 0.82
Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance. Blood (2013) 0.82
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. J Cancer (2014) 0.82
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer (2015) 0.81
PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer. Oncogene (2015) 0.81
In vitro and in vivo models for analysis of resistance to anticancer molecular therapies. Curr Med Chem (2014) 0.81
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLoS One (2014) 0.81
The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy? Contemp Oncol (Pozn) (2013) 0.81
Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells. Neoplasia (2013) 0.78
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther (2014) 0.78
Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int (2016) 0.77
High delta-like ligand 4 (DLL4) is correlated with peritumoral brain edema and predicts poor prognosis in primary glioblastoma. Medicine (Baltimore) (2014) 0.77
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs (2016) 0.76
Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget (2016) 0.76
Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene (2016) 0.75
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther (2016) 0.75
Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesis. Oncotarget (2015) 0.75
Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma. Mol Med Rep (2016) 0.75
Nox2 contributes to the arterial endothelial specification of mouse induced pluripotent stem cells by upregulating Notch signaling. Sci Rep (2016) 0.75
Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer. Oncotarget (2016) 0.75
Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. Cancer Biol Ther (2014) 0.75
Differential function and regulation of orphan nuclear receptor TR3 isoforms in endothelial cells. Tumour Biol (2015) 0.75
To branch or to expand? Elife (2016) 0.75
Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget (2017) 0.75
Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. Transl Oncol (2017) 0.75
Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene (2017) 0.75
Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers. J Clin Exp Oncol (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell (2010) 7.25
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 5.05
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine (2011) 3.79
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res (2011) 3.25
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 3.19
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res (2003) 2.93
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood (2005) 2.91
Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia (2002) 2.90
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell (2007) 2.69
Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res (2006) 2.68
Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res (2003) 2.61
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev (2007) 2.56
Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol (2012) 2.51
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol (2011) 2.45
Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab (2012) 2.43
A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem (2007) 2.34
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res (2002) 2.31
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res (2007) 2.31
Activating transcription factor 4. Int J Biochem Cell Biol (2007) 2.26
Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res (2003) 2.24
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics (2002) 2.21
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res (2005) 2.16
Diffusion limits of an in vitro thick prevascularized tissue. Tissue Eng (2005) 2.15
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res (2002) 2.13
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res (2007) 2.06
MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One (2010) 2.05
Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology (2005) 2.05
Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells (2003) 2.03
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res (2009) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet (2008) 2.00
Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res (2003) 1.99
Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res (2002) 1.98
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer (2010) 1.95
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell (2008) 1.94
Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med (2008) 1.93
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res (2006) 1.92
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol (2003) 1.92
Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells (2006) 1.90
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 1.90
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res (2002) 1.84
Severe polyposis in Apc(1322T) mice is associated with submaximal Wnt signalling and increased expression of the stem cell marker Lgr5. Gut (2010) 1.84
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res (2004) 1.83
New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood (2010) 1.82
MicroRNA-10b and breast cancer metastasis. Nature (2008) 1.80
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci (Landmark Ed) (2009) 1.76
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res (2007) 1.75
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res (2004) 1.75
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res (2002) 1.74
Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med (2009) 1.74
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol (2006) 1.74
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 1.74
The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem (2001) 1.72
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72